Status:
COMPLETED
SF-QUALIVEEN Turkish Validity and Reliability Study
Lead Sponsor:
Istanbul Aydın University
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
Urological dysfunction is common in patients with Multiple Sclerosis (MS) and its prevalence has been reported at a high rate of 32-97%. Bladder dysfunction is associated with a significant deteriorat...
Detailed Description
The aim of this study is to reveal the Turkish cultural adaptation, validity and reliability of the SF-Qualiveen scale. In our study, Sf-Qualiveen and Urogenital Distress Inventory (UDI-6) scales will...
Eligibility Criteria
Inclusion
- age 18-65;
- definitive diagnosis of MS according to McDonald criteria;
- ability to read and write in Turkish.
Exclusion
- acute attacks of MS (within 3 months);
- cognitive impairment (Mini Mental test result 24 points and below);
- any chronic disease other than MS;
- active malignant tumors;
- symptomatic urinary tract infections;
- patients who changed treatment within the test-retest period.
Key Trial Info
Start Date :
July 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2020
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04483609
Start Date
July 30 2020
End Date
October 30 2020
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
İstanbul Üniversitesi-Cerrahpaşa
Istanbul, Turkey (Türkiye)